Cigna (CI) Stock Forecast & Price Target

Cigna Group is attractive because its diversified model combines stable employer-focused health benefits with a scaled Evernorth PBM and specialty pharmacy platform that should support durable earnings growth. Management has already guided to at least $30.60 of 2026 adjusted EPS and at least 10% growth in 2027 off a roughly $30 baseline, while Cigna Healthcare delivered $11.7 billion of revenue and $1.2 billion of AOI with 85.0% MLR, showing solid execution and pricing discipline. Longer term, the stock is supported by high-90% PBM retention, at least 2 million new PBM customers in 2027, and a $3 billion savings program through 2030 that can expand margins and offset PBS transition pressure.

Cigna Group is facing a more skeptical fundamental setup because its reaffirmed CY26 adjusted EPS guidance of at least $30.45 and 10.0%-14.0% long-term growth target still imply a demanding path to a $45.00 CY30 floor, while the model now assumes lower 2027 EPS of $33.10 versus $33.65 previously. The case is further pressured by reduced segment momentum, with Pharmacy Benefit Services now modeled at 0.0% to 4.0% earnings growth and Evernorth AOI growth of about 2%, both below the company’s longer-term targets, alongside risks from rebate-free PBM transitions, slower biosimilar adoption, and client outmigration. Although capital deployment supports EPS, the 5-year cash flow outlook was cut to about $50.0B from roughly $60.0B, leaving less room to offset execution risk, especially as U.S. commercial membership remains sensitive to unemployment and healthcare cost trend management.